Loading company
TAKTakeda Pharmaceutical Company Limited$33.9BABuilt from Kiniksa Pharmaceuticals International, plc’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
The themes Kiniksa Pharmaceuticals International is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
KNSA · Nasdaq · Healthcare · Drug Manufacturers Specialty and Generic
$96.36+0.6%Nov 12 close
Figures through September 30, 2026, from the 10-Q filed October 27, 2026
Just reported
From Kiniksa Pharmaceuticals International's results release of October 27, 2026; its quarterly report has since been filed.
Actual
$286M
+58% y/y
+17% q/q
Guided
—
No guide given
Actual
$0.56
+143% y/y
+87% q/q
Guided
—
No guide given
Actual
$54.2M
+126% y/y
+99% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Grade A+
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 19 quarters of Kiniksa Pharmaceuticals International, plc’s grade history. The other 17 go back to February 2022.
